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Abstract: p53 over-expression has been proposed as a reliable marker associated to oral carcinogenesis, although only 
about 50% of oral carcinomas (OSCC) are associated with p53 over-expression and even p53-negative lesions can pro-
gress to OSCC. The aim of the study was to determine whether the combination of p53 over-expression and p53 low-
expression associated with Ki67 over-expression (high Ki67/p53 ratio) could lead to a more sensitive parameter. Immu-
nohistochemical expression of Ki67 and p53 was measured in 54 specimens from OSCC; 27 specimens from moder-
ate/severe epithelial dysplasia; 32 specimens from oral leukoplakias without epithelial dysplasia, and 13 specimens with 
normal epithelium. p53 over-expression was found in 31 (53%) samples from OSCC, in 10 (37%) samples from severe 
dysplasias, and in 5 (15%) samples from non-dysplastic lesions, while the combination of high p53 values with high 
Ki67/p53 ratio was observed in 93% of OSCC, in 81% of dysplastic lesions, and in 50% of non-dysplastic lesions. This 
parameter may have a clinical implication to detect early lesions with an impairment of p53 pathway, and probably at risk 
of progress to OSCC. 
INTRODUCTION  
  It has been widely demonstrated that most oral squamous 
cell carcinomas (OSCC) develop through their precancerous 
steps which are defined as potentially malignant lesions and 
are histologically characterized by increasing grades of 
epithelial dysplasia [1-4]. 
  So far, the only accepted method to quantify the risk of 
progression to OSCC of a potentially malignant lesion, is the 
presence/absence of histological findings of dysplasia [5-6], 
although the presence of dysplasia does not always indicate 
malignant transformation and its absence does not preclude it 
[7]. Moreover, histological assessment of dysplasia is ex-
tremely subjective and prone to inter and intra-observer 
variation [8], and additionally some potentially malignant 
lesions do not show dysplastic alterations [9-10].  
  These considerations have stimulated intense research in 
this area, and many studies have been conducted so far, in an 
attempt to find out molecular markers that are associated 
with OSCC and that can predict malignant transformation 
when found in epithelial precursor lesions, especially in 
cases without signs of dysplasia [11-13]. 
  The immunohistochemical analysis of p53 protein is a 
simple and inexpensive method that has been widely used 
for this purpose, and many studies have shown that it is in-
volved in oral carcinogenesis and its alteration occurs early 
in the process of neoplastic transformation, often preceding 
recognizable histological alterations [12-14-16]. 
  p53 over-expression has been widely demonstrated to be 
a reliable predictor of progression to OSCC, either if we con- 
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sider the over-expression as a physiologic response to induce 
cell cycle arrest in genetically altered hyper-proliferating 
cells or as a primary genetic defect leading to the production 
of high levels of mutated non-functional p53 protein; this is 
why the most utilized antibodies in the literature stain the 
total form of p53 protein and can not discriminate between 
wild or mutated form [17-18]. 
  However, p53 over-expression as a marker of progres-
sion to OSCC has not been considered highly sensitive, 
probably because only about 50% of OSCC are associated 
with over-expression of p53 protein [19-22].
 
  It follows that if the occurrence of p53 over-expression 
can be considered specific in detecting oral lesions at risk of 
developing p53-positive tumours, the presence of low p53 
values should be considered as non-informative for prognos-
tic purposes, since it can not distinguish between lesions 
with a genetically reduced production of p53 at high risk of 
developing p53-negative tumours, and lesions with a physio-
logical low p53 activity or lesions that follow different car-
cinogenic pathways in which the p53 abrogation does not 
play a role [7,11-22]. 
  It is well known that in non-neoplastic cells the expres-
sion of p53 is usually related to the cell proliferating rate, 
since p53 is considered as having an “oncogene checkpoint” 
function that guards cells against hyperproliferative signals 
[23].  
  It follows that in non-neoplastic cells that respond to pro-
liferative signals from inflammatory changes, traumas or 
hypoxia, a proportional increase in p53 activity should be 
expected [24-25].  
  Thus, we may assume that the finding of an increased 
proliferating rate associated to a depressed p53 expression 
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lesions might possibly identify genetically damaged lesions 
lacking of p53 protective role during cell cycling and may be 
at risk of progressing to p53-negative cancer. 
  In the present study, the Ki67 protein has been utilized as 
a immunohistochemical marker of proliferating cells [26], 
and samples with high Ki67/p53 ratio scores were taken into 
consideration together with samples with high p53 scores to 
determine whether this combination of scores could be use-
ful to discriminate oral lesions with an impaired cell turn-
over.  
MATERIALS AND METHODOLOGY 
  A total of 126 biopsy samples from 126 consecutive pa-
tients who have referred to the Department of Oral Sciences 
of the University of Bologna, Bologna (Italy) between Janu-
ary 2004 to September 2006 were analyzed: 54 specimens 
from infiltrating OSCC, 27 from moderate/severe epithelial 
dysplasias (19 from non-tumoral areas adjacent to OSCC 
included in the study, and 8 from oral leukoplakias), 32 from 
oral leukoplakias with epithelial hyperplasias and no signs of 
dysplasia, and 13 from normal epithelium oral mucosa ob-
tained during third molar removal or as part of the excision 
of benign conditions. All samples underwent histological and 
immunohistochemical analysis. 
  Histological diagnoses were performed at the Department 
of Pathology of the University of Bologna, at Bellaria Hospi-
tal (Bologna, Italy), following the criteria describe in the 
WHO book. Specifically moderate\severe dysplasia (atypical 
hyperplasia according to the Ljubljiana classification) was 
characterized by increasing atypia, loss of polarity, and fre-
quent mitoses, involving more than two-third of the epithe-
lium while lacking infiltrative growth. Squamous cell Hy-
perplasia (Simple hyperplasia, according to the Ljubljiana 
classification) was characterized by increased basal-
parabasal layers, acanthosis, in absence of architectural al-
terations [6]. No cases of mild dysplasia were included in the 
study. The rationale to only select lesions with high grades 
of dysplasia, was to be sure about the effective presence of 
dysplasia by reducing the subjectivity of its assessment and 
their well established relative high rate of malignant trans-
formation [8,27]; this to well differentiate the group of le-
sions with dysplasia from that of hyperplastic lesions. 
  Immunostaining was performed on 2-m thick sections 
serially cut from the selected blocks. The following antibod-
ies were employed: monoclonal anti-Ki67 (Dako, Denmark, 
clone MIB-1, diluted 1:200) and monoclonal anti-p53 (Dako, 
clone p53, diluted 1:50). The processing was performed in 
an automatic stainer (Autostainer, Ventana, USA). All the 
cases contained an internal control as basal cells of the oral 
epithelium show nuclear positivity for the two markers under 
study. Negative controls consisted in omitting the primary 
antibody. Counting the percentage of positive nuclei in 400 
consecutive epithelial cells of selected areas representative of 
the lesion gave a semi-quantitative evaluation of the immu-
nohistochemical results. Fig. (1) shows an example of posi-
tive and negative staining of p53 protein. 
Statistical Analysis 
  One-variable analysis was performed on p53 values and 
Ki67/p53 ratio to collect summary statistics, and density 
trace diagrams were used to obtain the shape of distribution 











Fig. (1). In normal oral mucosa p53 positivity is limited to rare 
basal keratinocytes (a); in this case with marked hyperkeratosis the 
p53 antibody stains the nuclei of numerous basal and suprabasal 
keratinocyte (b). 
  We established the cut-off value for p53 and Ki67 over-
expression as 20% staining and for high Ki67/p53 ratio as 3 
because no sample from normal mucosa showed higher val-
ues both in the present and in a previously published study 
[24]. 
  Thus high p53 (p53 over-expression) were considered 
when equal or more than 20%, while high Ki67/p53 ratio 
was considered when equal or more than 3. 
  A multiple logistic regression model was fitted to de-
scribe the relationship between the presence/absence of dys-
plasia (dependent variables) or between dysplasia and OSCC 
(dependent variables) and 2 independent variables: p53 over-
expression versus p53 low expression, and the combination 
of samples with high p53 and samples with high Ki67/p53 
ratio versus low p53 and low Ki67/p53 ratio. 
  One-way ANOVA was used to compare p53 mean values 
(continuous dependent variable) between samples from 
OSCC, epithelial hyperplasia, epithelial dysplasia and con-
trols (nominal independent variable). Fisher’s least signifi-
cant difference procedure (LSD) was the method to dis-
criminate among the means at 95.0% confidence level. 
RESULTS 
  One-way ANOVA showed that the mean p53 value in 
OSCC (38.4±34.9) was significantly higher (F=8.8; p<.01) 
than those found in controls and in oral lesions either with or 
without dysplasia (respectively, 8.3± 3.5, 21.3±27.1, and 
10.8 ±6.9). Fisher’s least significant difference procedure did 
not show any difference between the last three groups (Fig. 
2). The wide Standard Deviation in samples from OSCC and 
oral lesions with dysplasia is the consequence of the con-
temporary presence of high and low p53 values in these oral 
lesions as documented by the density trace diagrams in Fig. 
(3). 
  Normal mucosa: the density trace diagram from normal 
samples showed a shape of distribution of p53 values charac-
terized by a single peak with a median of 10% (range 5-15), 
and values always less or equal to 15%. The sample come 
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from a normal distribution with a standardized skewness 
(.74) and kurtosis (-.17) values within a range expected from 












Fig. (2). Mean p53 values in controls, hyperplasia, dysplasia and 
OSCC. 
  The Ki67/p53 ratio showed a range from 0.5 to 1.5 with a 
median of 1 and values never exceeding 2.5.  
  OSCC: the density trace diagram from OSCC showed a 
shape of distribution of p53 values characterized by two well 
defined peaks that distinguished two very different popula-
tion where high or low p53 values were expressed respec-
tively in 31 (57%) and 23 (43%) samples (Fig. 3d).  
  A Ki67/p53 ratio equal or more than 3 was found in 19 
patients out of 23 (83%) showing low p53 values (Table 1). 
All samples with high p53 values had low Ki67/p53 ratios. 
  Epithelial Dysplasia: similarly to OSCC the shape of 
distribution of p53 values showed two well defined peaks 
where high values are expressed respectively in 10 (37%) 
samples of which 8 (42%) from non-tumoral areas adjacent 
to OSCC (Fig. 3c). High Ki67/p53 ratio was found in 12 out 
of 17 (71%) samples with low p53 values of which 9 (82%) 
from margins of OSCC (Table 1). All samples with high p53 
values had low Ki67/p53 ratios. 
  Epithelial Hyperplasia: high p53 values were found in 5 
(15%) samples (Fig. 3b), and high Ki67/p53 ratio was found 
in 11 out of 27 (37%) samples with low p53 values (Table 
1). Again, all samples with high p53 values had low 
Ki67/p53 ratios. 
  The combination of high p53 values with high Ki67/p53 
ratio was observed in 93% (50 out of 54) of OSCC and in 
81% (22 out of 27) of epithelial dysplasias, of which 89% 
(17 out of 19) from non-tumoral areas adjacent to OSCC, 
and in 50% (16 out of 32) of epithelial hyperplasias, while it 
was never observed in any sample from normal mucosa. Ta-
ble 1 summarizes the results.  
  The results of fitting a multiple logistic regression model 
to describe the relationship between the presence/absence of 
dysplasia and the 2 independent variables (p53 over-
expression versus p53 low expression, and the combination 
of samples with high p53 and samples with high Ki67/p53 
ratio versus low p53 and low Ki67/p53 ratio) showed that the 
only parameter related to the presence/absence of dysplasia 
and reaching the significance (Chi square 6.6; p<.01) was the 
presence/absence of samples with high p53 associated with 













Fig. (3). Density trace diagrams showing p53 distribution in speci-
mens from normal mucosa (a), epithelial hyperplasias (b), epithelial 
dysplasias (c) and OSCC (d). 
 
Table  1.  Number (%) of Specimens with p53 Over-Expres- 
sion and Specimens with p53 Over-Expression Asso- 
ciated with Samples with High Ki67/p53 Ratio from 
Normal Mucosa, Epithelial Hyperplasias, Epithelial 
Dysplasias and OSCC 







number 13  32 27  54 
Samples with p53 
over-expression 
0 (0%)  5 (15%)  10(37%)  31(57%) 
Samples with p53 
over-expression 
associated with 
samples with high 
Ki67/p53 ratio. 
0 (0%)  16 (50%)  22 (81%)  50(93%) 
 
  No significant difference was found between OSCC and 
epithelial dysplasia when this combination was utilized (Chi 
square .31; ns). 
DISCUSSION 
  It is widely accepted that OSCC develops as a result of 
accumulation of genetic errors in the same tissue [28,29], 
and that mutations in the TP53 gene leading to loss of func-
tion is one the most common genetic damage found in hu-
man tumour and in OSCC [30-32]. 
 
  TP53 mutations may result in a over-production of p53 
inactive proteins which accumulate in the epithelium either 
due to blocking by another protein or due to partial degrada-
tion [32], or instead in a abrogation of p53 wild function by 
epigenetic mechanisms, due to a mutation that did not result 
in a stable form of the p53 protein [33]. This can be well 
evidentiated by immunohistochemical analysis of paraffin Predictive Role of p53 Protein as a Single Marker  The Open Dentistry Journal, 2008, Volume 2    27 
embedded specimens showing staining of a high number of 
neoplastic cells in the first event or complete negative stain-
ing in the latter cases [34]. 
  The shape of distribution of p53 values from OSCC in 
the present study, is in line with this statement, clearly show-
ing the presence of two well defined peaks that distinguish 
two very different OSCC population, where high or low p53 
values were expressed respectively in about 57% and 43% of 
cases. The prevalence of higher p53 values in the entire 
population explains the statistical difference in the mean p53 
values between malignant samples and samples from normal 
mucosa. 
  The evidence that the p53 pathway is very important in 
the biology of oral cancer has led to the application of such 
immunohistochemical analysis as a simple rapid and inex-
pensive method to potentially malignant lesions in an at-
tempt to find a useful marker to predict progression to 
OSCC. 
  Higher mean p53 values with respect to normal mucosa 
has been demonstrated in lesions with and without signs of 
dysplasia and it has been documented that lesions progressed 
to OSCC showed p53 over-expression early during the proc-
ess, although most of the studies in the literature have util-
ized antibodies that can not discriminate between wild or 
mutated form [13,35-36]. Nevertheless, studies that calculate 
the positive and negative predictive value are still lacking. 
  In our study we did not find significantly higher p53 
mean values in potentially malignant lesions with respect to 
normal mucosa although samples from lesions with severe 
dysplastic alterations showed higher mean p53 value than 
normal mucosa, but did not reach statistical significance. The 
limited number of controls may have contributed to hide a 
significant difference between p53 mean values from poten-
tially malignant lesions and normal mucosa, although all p53 
values from normal mucosa kept lower than the cut-off con-
sidered in the present and in a previously published study 
[24].  
  However, p53 analysis did reveal differences between 
our potentially malignant lesions and normal mucosa since 
about 40% of sample in the group of dysplastic lesions and 
15% in the group of leukoplakias without dysplastic altera-
tions showed p53 values higher than the maximum value 
found in normal mucosa. We suppose that the prevalence of 
normal or low values in dysplastic lesions can explain the 
lack of statistical difference in the mean p53 values between 
pre-malignant lesions and normal mucosa. 
  When concerning lesions with low p53 expression, the 
present data showed that low staining was present in more 
than 40% of OSCC, and even in about 60% of lesions with 
severe dysplasia, most of them at margins of OSCC and 
probably precursors of p53-negative tumours [7]. 
  If we take the p53 over-expression as a predictive 
marker, the occurrence of positive samples in our population 
is probably too low to discriminate lesions at “high risk” of 
malignancy, also considering that not all p53-positive lesions 
will progress to cancer [37]. 
  Furthermore, if we consider samples with low p53 ex-
pression as lesions “not at risk” of developing cancer, the 
occurrence of p53-negative lesions in our population of se-
vere epithelial dysplasias is too high, considering that most 
of them were situated at margins of OSCC and thus at very 
high risk of malignant changes [38-39].  
  These data underline the low predictive value of p53 
when used as a single marker, since the high occurrence of 
low p53 staining in pre-malignant lesions is very difficult to 
be interpreted and not enough to rule out the progression to 
OSCC.  
  This is in agreement with many reports that have stated 
that p53 has a good specificity, i.e the likelihood of malig-
nant transformation is high when it is over-expressed, but a 
low sensitivity since the absence of p53 staining did not pre-
clude malignant transformation in a considerable proportion 
of pre-malignant lesions [20,40-41]. 
  Instead, in the presence of a lesion in predicate to de-
velop cancer, the avoidance of false-negative results takes 
priority, so as not to miss patients who actually have a dis-
ease at risk of developing OSCC; in this situation, the sensi-
tivity is most important to maximize negative-predictive 
accuracy, i.e. the likelihood that a negative test relates to the 
absence of any risk of malignancy [42].  
  To this direction have gone our results obtained by the 
combination of samples with high p53 values and samples 
with low p53 values but high Ki67 values, i.e. a high 
Ki67/p53 ratio.  
  We utilized this approach to see whether the presence of 
an increased mitotic activity not associated to an increased 
p53 activity might discriminate lesions with high prolifera-
tive activity where the presence of a genetic damage prevents 
a reactive stimulation of p53. 
  The rationale was that in non-neoplastic cells, an in-
creased cell proliferation due to a series of factors such in-
flammation, trauma etc, usually elicits a p53 protein accumu-
lation that is considered to be a physiologic response to the 
increased proliferation rate of keratinocytes as a guardian of 
epithelial growth [43-44]. 
  In the present study, high Ki67/p53 ratios were found in 
83% of OSCC with low p53 expression and even in 71% of 
severe epithelial dysplasias with low p53 values, and the 
combination of samples with p53 over-expression and sam-
ples with low p53 values but high Ki67/p53 ratio, led to a 
very high association with OSCC and epithelial dysplasias. 
About 90% of both OSCC and epithelial dysplasias were 
positive to this combination, while normal epithelium never 
was.  
  Dysplasia is still now the most important predictive fac-
tor providing a surgical or non-surgical therapeutic approach. 
However histological assessment of dysplasia is extremely 
subjective [8], and some potentially malignant lesions do not 
show dysplastic alterations [9-10]. For these reasons, it 
would be very important to found alternative parameters that 
allow an early detection of pre-neoplastic lesions without 
any dysplastic changes. The evaluation of p53 associated 
with Ki67, when applied to potentially malignant lesions 
without features of dysplasia could be useful to enable the 
detection of cell alterations in such lesions.  
  In the present study, the combination of p53-over-expres- 
sion and high Ki67/p53 ratio was present in about 50% of 
leukoplakias without signs of dysplasia. 28    The Open Dentistry Journal, 2008, Volume 2  Montebugnoli et al. 
  This percentage surely overestimates the risk of develop-
ing cancer, but could be useful to increase the predictive 
sensitivity and to rule out at least 50% of lesions with a pre-
sumably very low risk of developing OSCC.  
CONCLUSIONS 
  p53 immunostaining as a single marker can not be con-
sidered a sensitive marker that would help to assess the de-
gree of cell alteration in oral lesions at risk of developing 
cancer. 
  While it could be accepted that p53 over-expression in 
potentially malignant lesions may indicate a risk of develop-
ing cancer, the occurrence of low p53 staining is very diffi-
cult to be interpreted and does not rule out a possible link to 
oral carcinogenesis.  
  In the present study the combination of p53 over-
expression and high Ki67/p53 ratio seemed to better associ-
ate with the occurrence of OSCC and severe epithelial dys-
plasia, and may have a routine implication as an easy method 
to early detect oral lesions with an impairment of p53 path-
way, and probably at risk of developing OSCC.  
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